FOXM1 and ovarian cancer: FOXM1 was previously reported that it correlates with chemoresistance in cancer cells and patients [13,14,21,26] and is upregulated in ovarian cancer cells after cisplatin treatment [14], and its overexpression in some cancers contributes to paclitaxel resistance [15,21,27].